tetano
Editor, Senior Moderator
Appl Microbiol Biotechnol. 2019 Jun 24. doi: 10.1007/s00253-019-09919-4. [Epub ahead of print]
[h=1]A LAG3-interfering oligonucleotide acts as an adjuvant to enhance the antibody responses induced by recombinant protein vaccines and inactivated influenza virus vaccines.[/h] Li Z[SUP]1[/SUP], Song Y[SUP]1[/SUP], Cui C[SUP]1[/SUP], Lan Y[SUP]2[/SUP], Li X[SUP]2[/SUP], Liu Y[SUP]2[/SUP], Lu F[SUP]2[/SUP], Zhang Y[SUP]2[/SUP], Yu Y[SUP]3[/SUP], Wang L[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Lymphocyte activation gene-3 (LAG3) is a transmembrane protein expressed on activated T cells and delivers inhibitory signals to render the T cells unable to effectively help B cells to produce antibodies to microbes and vaccines. Presumably, antagonizing LAG3 could enhance the antibody responses to vaccines, and LAG3 antagonists could facilitate vaccines to induce vigorous antibody responses. In this study, we designed a LAG3-interfering antisense oligonucleotide, designated as LIO-1. The LIO-1 is complementary to an identical region shared in human and mouse LAG3 mRNA. We demonstrated that LIO-1 induced the degradation of LAG3 mRNA in immune cells, decreased the LAG3 expression on CD4[SUP]+[/SUP] T cells, maintained the prolonged proliferation and promoted the activation of antigen-specific CD4[SUP]+[/SUP] T cells, and increased the production of IFN-γ, IL-2, and IL-6 in the antigen re-stimulated immune cells. In addition, we found that LIO-1 enhanced the antibody responses induced by ISA35-formulated recombinant antigen vaccine or ISA35-formulated inactivated influenza virus vaccines in mice. Thus, the LIO-1, a nucleic acid LAG3 antagonist, could facilitate vaccines to induce vigorous antibody responses and has the possibility to be used as a novel adjuvant.
[h=4]KEYWORDS:[/h] Antisense oligonucleotide; Lymphocyte activation gene-3; T cell; Vaccine
PMID: 31236615 DOI: 10.1007/s00253-019-09919-4
[h=1]A LAG3-interfering oligonucleotide acts as an adjuvant to enhance the antibody responses induced by recombinant protein vaccines and inactivated influenza virus vaccines.[/h] Li Z[SUP]1[/SUP], Song Y[SUP]1[/SUP], Cui C[SUP]1[/SUP], Lan Y[SUP]2[/SUP], Li X[SUP]2[/SUP], Liu Y[SUP]2[/SUP], Lu F[SUP]2[/SUP], Zhang Y[SUP]2[/SUP], Yu Y[SUP]3[/SUP], Wang L[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Lymphocyte activation gene-3 (LAG3) is a transmembrane protein expressed on activated T cells and delivers inhibitory signals to render the T cells unable to effectively help B cells to produce antibodies to microbes and vaccines. Presumably, antagonizing LAG3 could enhance the antibody responses to vaccines, and LAG3 antagonists could facilitate vaccines to induce vigorous antibody responses. In this study, we designed a LAG3-interfering antisense oligonucleotide, designated as LIO-1. The LIO-1 is complementary to an identical region shared in human and mouse LAG3 mRNA. We demonstrated that LIO-1 induced the degradation of LAG3 mRNA in immune cells, decreased the LAG3 expression on CD4[SUP]+[/SUP] T cells, maintained the prolonged proliferation and promoted the activation of antigen-specific CD4[SUP]+[/SUP] T cells, and increased the production of IFN-γ, IL-2, and IL-6 in the antigen re-stimulated immune cells. In addition, we found that LIO-1 enhanced the antibody responses induced by ISA35-formulated recombinant antigen vaccine or ISA35-formulated inactivated influenza virus vaccines in mice. Thus, the LIO-1, a nucleic acid LAG3 antagonist, could facilitate vaccines to induce vigorous antibody responses and has the possibility to be used as a novel adjuvant.
[h=4]KEYWORDS:[/h] Antisense oligonucleotide; Lymphocyte activation gene-3; T cell; Vaccine
PMID: 31236615 DOI: 10.1007/s00253-019-09919-4